Arend G. J. Aalbers

Arend G. J. Aalbers

Auto-generated profile, based on publicly available information

Arend G. J. Aalbers

Dept. of Surgery, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, the Netherlands

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2019 in Journal of Biomedical Optics
Verified
Journal Article
Open access
PDF file
EBElisabeth J. M. Baltussen
Elisabeth J. M. Baltussen
EKEsther N. D. Kok
Esther N. D. Kok
SKSusan G. Brouwer de Koning
Susan G. Brouwer de Koning
JSJoyce Sanders
Joyce Sanders
AAArend G. J. Aalbers
Arend G. J. Aalbers
TRTheo J. M. Ruers
Theo J. M. Ruers
Colorectal cancer is the third most commonly diagnosed cancer worldwide and the fourth cause of death due to cancer.1,2 For patients with colorectal cancer, surgery is the cornerstone of the treatment. In the last decades, laparoscopic surgery for colorectal cancer has become common practice. Randomized controlled trials have proven similar clinical outcomes for laparoscopic surgery as for open surgery with a decrease in hospital stay.3 One of the drawbacks of laparoscopic surgery is the reduced tactile feedback during surgery.4,5 The lack of tactile feedback makes tissue recognition more cumbersome, especially in areas where radical resection margins are often compromised, like in locally advanced tumors and in rectal cancer. Hence, an alternative technique that would enable the surgeon to distinguish tumor from normal tissue during laparoscopic surgery in real-time would be of great benefit to secure radical resection in difficult areas, such as in rectal cancer. We will investigate the use of hyperspectral imaging (HSI) as a tool to ensure radical margins in these circumstances, distinguishing tumor from healthy colorectal tissue.

13 July 2017 in JMIR Research Protocols
Verified
Journal Article
Open access
RKRosa T van der Kaaij
Rosa T van der Kaaij
HBHidde Jw Braam
Hidde Jw Braam
HBHenk Boot
Henk Boot
MLMaartje Los
Maartje Los
ACAnnemieke Cats
Annemieke Cats
JSJohanna W van Sandick
Johanna W van Sandick
Patients with gastric cancer and peritoneal carcinomatosis have a very poor prognosis; median survival is 3 to 4 months. Palliative systemic chemotherapy is currently the only treatment available in the Netherlands. Intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) has an established role in the treatment of peritoneal carcinomatosis originating from colorectal cancer, appendiceal cancer, and pseudomyxoma peritonei; its role in gastric cancer is uncertain. Currently, there is no consensus on the choice of chemotherapeutic agents used in HIPEC for gastric cancer. The main objectives of this study are (1) to investigate the safety, tolerability, and feasibility of gastrectomy combined with cytoreductive surgery and HIPEC after systemic chemotherapy, as a primary treatment option for patients with advanced gastric cancer with tumor positive peritoneal cytology and/or limited peritoneal carcinomatosis; and (2) to determine the maximum tolerated dose (MTD) of intraperitoneal docetaxel in combination with a fixed dose of intraperitoneal oxaliplatin. The PERISCOPE study is a multicenter, open label, phase I-II dose-escalation study. The MTD of docetaxel will be studied using a 3+3 design. Patients with locally advanced (cT3-cT4) gastric adenocarcinoma are eligible for inclusion if the primary gastric tumor is considered resectable, tumor positive peritoneal cytology and/or limited peritoneal carcinomatosis is confirmed by diagnostic laparoscopy/ laparotomy, and prior systemic chemotherapy was without disease progression. At laparotomy, cytoreductive surgery (complete removal of all macroscopically visible tumor deposits) and a total or partial gastrectomy with a D2 lymph node dissection is performed. An open HIPEC technique is used with 460mg/m2 hyperthermic oxaliplatin for 30 minutes (41°C to 42°C) followed by normothermic docetaxel for 90 minutes (37°C) in a dose that will be escalated per 3 patients (0, 50, 75, 100, 125, 150 mg/m2). The primary endpoint is treatment related toxicity. Patient accrual is ongoing and the first results are expected in 2017. The PERISCOPE study will determine the safety, tolerability, and feasibility of gastrectomy combined with cytoreduction and HIPEC using oxaliplatin in combination with docetaxel after systemic chemotherapy as primary treatment option for gastric cancer patients with tumor positive peritoneal cytology and/or limited peritoneal carcinomatosis. This study will provide pharmacokinetic data on the intraperitoneal administration of oxaliplatin and docetaxel, including the MTD of intraperitoneal-administered docetaxel. These data are a prerequisite for the safe conduct of future HIPEC studies in patients with gastric cancer. Netherlands Trial Registration (NTR): NTR4250; http://www.trialregister.nl/trialreg/admin/ rctview.asp?TC=4250 (Archived by WebCite at http://www.webcitation.org/6rWJONgkt).

26 February 2022 in Gynecologic Oncology Reports
Verified
Journal Article
Open access
RSRuby M. van Stein
Ruby M. van Stein
CLChristianne Lok
Christianne Lok
AAArend G.J. Aalbers
Arend G.J. Aalbers
IHIgnace de Hingh
Ignace de Hingh
AHAletta P.I. Houwink
Aletta P.I. Houwink
WDWillemien J. van Driel
Willemien J. van Driel
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is standard of care in the Netherlands in patients with stage III epithelial ovarian cancer following interval cytoreductive surgery (CRS). Differences in patient selection, technical aspects, and perioperative management exist between centers performing HIPEC. Standardization aims to reduce unwanted variation in clinical practice. As part of an implementation process, we aimed to standardize perioperative care for patients treated with CRS and HIPEC using a Delphi-based consensus approach. We performed a two-phase modified Delphi method involving a multidisciplinary panel of 40 experts who completed a survey on CRS and HIPEC. During a consensus meeting, survey outcomes and available scientific evidence was discussed. Items without consensus (<75% agreement) were adjusted and evaluated in a second survey. Consensus was reached in the first round on 51% of items. After two rounds, consensus was reached on the majority of items (82%) including patient selection, preoperative workup, technical aspects of CRS and HIPEC, and postoperative care. No consensus was reached on the role of HIPEC in rare ovarian cancer types, preoperative bowel preparation, timing to create bowel anastomoses, and manipulation of the perfusate. Dutch experts reached consensus on most items regarding interval CRS and HIPEC for ovarian cancer. This consensus study may help to align treatment protocols and to minimize practice variation. Topics without consensus may be put on the research agenda of HIPEC for ovarian cancer.

1 December 2017 in European Journal of Trauma & Dissociation
Verified
Journal Article
Closed access
KWK.S. Wegen
K.S. Wegen
ADA. van Dijke
A. van Dijke
AAA. Aalbers
A. Aalbers
AZA.M.E.E. Zedlitz
A.M.E.E. Zedlitz

11 December 2021 in Abdominal Radiology
Verified
Journal Article
Closed access
PDF file
MEMaurits P. Engbersen
Maurits P. Engbersen
ENElias Nerad
Elias Nerad
CRCharlotte J. V. Rijsemus
Charlotte J. V. Rijsemus
TBTineke Buffart
Tineke Buffart
RBRegina G. H. Beets-Tan
Regina G. H. Beets-Tan
MLMax J. Lahaye
Max J. Lahaye

7 November 2022 in Journal of Plastic Surgery and Hand Surgery
Verified
Journal Article
Closed access
MLMaurits Lange
Maurits Lange
JHJ. Joris Hage
J. Joris Hage
AAArend Aalbers
Arend Aalbers
EWEsther M. K. Wit
Esther M. K. Wit
FAFrédéric Amant
Frédéric Amant
MHMarije J. Hoornweg
Marije J. Hoornweg
Primary intra- or transabdominal transplantation of an extended rectus abdominis myocutaneous (ERAM) flap may help prevent surgical complications of pelvic resections. Surgical delay of the ERAM flap may help prevent intra-abdominal (partial) flap loss after transplantation in highly complex situations including previous irradiation. We report on the outcome of this approach and the risk-factors associated with an eventful outcome. From 2012 to 2020, 105 delayed ERAM flaps were consecutively applied immediately following extended pelvic resections after chemoradiation or hyperthermic intraperitoneal chemotherapy. We addressed the increased reconstructive demands by designing the flap in line with the 10th rib and delaying the flap’s skin island. All post-operative complications were assessed in light of patient-related or procedure-related potential risk-factors. Major complications occurred in 39 patients. These were correlated with surgery for residual or recurrent malignancy (p < 0.01), with tip necrosis after flap delay (p = 0.02), and with the use of a mesh to close the abdominal donor site (p < 0.01). (Partial) flap loss occurred in 4 cases. We observed a comparably high rate of major complications after ERAM transplantations for increasingly extending indications of perineal-pelvic resections. We consider this to be attributable to poorer patients’ conditions and disease processes, rather than to flap viability. Delay of the flap allowed for the use of large and voluminous flaps with comparably little (partial) flap loss.